Moolec Science (MLEC) investor relations material

Executive summary

• Achieved major scientific, operational, and regulatory milestones in FY2024, including USDA-APHIS approval for PiggySooy and the first commercial planting of GLASO in the US.

• Established and expanded molecular biology labs in Texas, centralizing R&D and improving efficiency.

• Signed a three-year offtake agreement with a major global CPG company for GLASO, marking the first US commercial entry.

• Entered an R&D collaboration with Bunge to enhance safflower productivity and expand market applications.

• Maintained prudent cash burn and strengthened liquidity through successful capital raises.

Financial highlights

• FY2024 revenue and other income rose to $5.8M–$6M, up from $0.94M–$1M in FY2023, driven by the soy protein ingredient business.

• Cost of sales increased to $4.5M, with SG&A and R&D expenses rising to $9.3M.

• Loss from operations widened to $7.52M from $4.81M year-over-year.

• Cash used in operating activities increased to $9.3M, with cash and cash equivalents at year-end at $5.39M.

• Maintained controlled cash burn, supporting growth and reducing accounts payable.

Outlook and guidance

• FY2025 expected to be pivotal, with GLASO commercialization, new revenue streams, and commercial expansion anticipated.

• GLASO projected to contribute about 15% of total revenue in FY2025, with potential to double in FY2026.

• Continued focus on operational efficiency, regulatory progress, and expanding the innovation pipeline.

• Plans to consolidate US operations, expand sales and marketing, and increase industry presence.

• Preparing for the commercial launch of GLASO and structured growth to support product launches.